# Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

> **NCT07463599** · PHASE1,PHASE2 · RECRUITING · sponsor: **HonorHealth Research Institute** · enrollment: 126 (estimated)

## Conditions studied

- Metastatic Colorectal Carcinoma (mCRC)
- Colorectal Cancer (CRC)
- Adenomatous Polyposis Coli (APC) Gene Mutation
- Catenin Beta-1 (CTNNB1) Gene Mutation

## Interventions

- **DRUG:** Tegavivint

## Key facts

- **NCT ID:** NCT07463599
- **Lead sponsor:** HonorHealth Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-17
- **Primary completion:** 2029-01
- **Final completion:** 2029-07
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07463599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07463599, "Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07463599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*